Company logo

PASG - Passage Bio, Inc.

NASDAQ -> Healthcare -> Biotechnology
Philadelphia, United States
Type: Equity

PASG price evolution
PASG
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $21.71 $33.58 $30.29 $33.37
Short term investments $92.58 $99.2 $121.19 $134.4
Net receivables
Inventory
Total current assets $117.96 $135.71 $153.63 $171.62
Long term investments
Property, plant & equipment $32.15 $33.11 $39.64 $41.19
Goodwill & intangible assets
Total noncurrent assets $32.59 $33.55 $40.07 $41.62
Total investments $92.58 $99.2 $121.19 $134.4
Total assets $150.54 $169.26 $193.7 $213.24
Current liabilities
Accounts payable $1.3 $2.75 $3.38 $3.03
Deferred revenue
Short long term debt $3.37 $3.35 $3.33 $3.3
Total current liabilities $16.34 $19.81 $19.87 $17.24
Long term debt $22.92 $23.17 $23.41 $23.65
Total noncurrent liabilities $22.92 $23.17 $23.41 $25.65
Total debt $26.29 $26.52 $26.74 $26.95
Total liabilities $39.26 $42.98 $43.28 $42.89
Shareholders' equity
Retained earnings -$594.47 -$577.71 -$550.6 -$526.74
Other shareholder equity -$0.04 -$0.19 -$0.34 -$0.43
Total shareholder equity $111.28 $126.28 $150.41 $170.35
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $21.71 $34.6 $128.97 $135
Short term investments $92.58 $155.01 $186.81 $169.81
Net receivables
Inventory
Total current assets $117.96 $197.04 $325.07 $317.18
Long term investments
Property, plant & equipment $32.15 $42.24 $23.81 $2.79
Goodwill & intangible assets
Total noncurrent assets $32.59 $46.51 $30.01 $10.82
Total investments $92.58 $155.01 $186.81 $169.81
Total assets $150.54 $243.55 $355.08 $328.01
Current liabilities
Accounts payable $1.3 $4.07 $9.45 $5.26
Deferred revenue
Short long term debt $3.37 $3.27
Total current liabilities $16.34 $18.35 $29.5 $21.18
Long term debt $22.92 $23.83
Total noncurrent liabilities $22.92 $23.83 $6.92 $2.12
Total debt $26.29 $27.11
Total liabilities $39.26 $42.18 $36.42 $23.29
Shareholders' equity
Retained earnings -$594.47 -$492.41 -$356.28 -$170.9
Other shareholder equity -$0.04 -$0.97 -$0.41 -$0.01
Total shareholder equity $111.28 $201.37 $318.66 $304.71
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $12.16 $15.1 $17.32 $16.84
Selling, general & administrative $6.29 $8.18 $8.06 $19.05
Total operating expenses $16.76 $27.11 $23.86 $34.34
Operating income -$16.76 -$27.11 -$23.86 -$34.34
Income from continuing operations
EBIT -$16.76 -$27.11 -$23.86 -$34.34
Income tax expense
Interest expense
Net income
Net income -$16.76 -$27.11 -$23.86 -$34.34
Income (for common shares) -$16.76 -$27.11 -$23.86 -$34.34
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $61.42 $86.05 $117.67 $81.79
Selling, general & administrative $41.58 $49.34 $60.06 $30.11
Total operating expenses $102.06 $138.39 $185.73 $112.9
Operating income -$102.06 -$138.39 -$185.73 -$112.9
Income from continuing operations
EBIT -$102.06 -$136.13 -$185.39 -$112.23
Income tax expense
Interest expense
Net income
Net income -$102.06 -$136.13 -$185.39 -$112.23
Income (for common shares) -$102.06 -$136.13 -$185.39 -$112.23
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$16.76 -$27.11 -$23.86 -$34.34
Operating activities
Depreciation $0.81 $0.96 $0.98 $0.98
Business acquisitions & disposals
Stock-based compensation $1.57 $2.82 $3.74 $2.78
Total cash flows from operations -$19.52 -$19.16 -$17.14 -$22.45
Investing activities
Capital expenditures -$0.01 -$0 -$0.1 -$0.03
Investments $7.61 $22.45 $14.07 $21.24
Total cash flows from investing $7.6 $22.45 $13.97 $21.22
Financing activities
Dividends paid
Sale and purchase of stock $0.05 $0.09
Net borrowings
Total cash flows from financing $0.05 $0.09
Effect of exchange rate
Change in cash and equivalents -$11.87 $3.29 -$3.08 -$1.23
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$102.06 -$136.13 -$185.39 -$112.23
Operating activities
Depreciation $3.72 $3.68 $1.54 $0.8
Business acquisitions & disposals
Stock-based compensation $10.92 $18.95 $32.69 $14.58
Total cash flows from operations -$78.26 -$118.21 -$126.88 -$80.52
Investing activities
Capital expenditures -$0.15 -$5.27 -$25.64 -$1.15
Investments $65.38 $30.47 -$20.17 -$170.46
Total cash flows from investing $65.24 $25.2 -$45.81 -$172.11
Financing activities
Dividends paid
Sale and purchase of stock $0.14 $0.43 $166.99 $228.75
Net borrowings -$1.79
Total cash flows from financing $0.14 -$1.35 $166.66 $228.75
Effect of exchange rate
Change in cash and equivalents -$12.89 -$94.36 -$6.04 -$23.87
Fundamentals
Market cap $62.64M
Enterprise value $67.22M
Shares outstanding 54.94M
Revenue $0.00
EBITDA -$98.34M
EBIT -$102.06M
Net Income -$102.06M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.61
EV/Sales N/A
EV/EBITDA -0.68
EV/EBIT -0.66
P/S ratio N/A
P/B ratio 0.56
Book/Share 2.03
Cash/Share 0.40
EPS -$1.86
ROA -56.18%
ROE -73.12%
Debt/Equity 0.35
Net debt/EBITDA -0.18
Current ratio 7.22
Quick ratio 7.22